Palacian i have a question about the 'toxic financing'. I would have expected the OS to have risen in the recent 10Q, ie. dilution, but there was no change. I don't understand how the financing is holding the price down if not dilution. any info in this regard would be appreciated.
Well maybe I'm right paladinski. Lower lows stopped last year. I've only been in this stock since then. Trend, though, looks to be UP to me. It's a biotech. There is no reasoning for ANY data. It doesn't matter if they have bad financing. All that crap IS irrelevant. Potential IS everything. How many micro biotechs actually have a revenue?? and what is their stock price. Speculative? absolutely. Feasable, more than likely!!
News 
Market Data 
Discover 
AI
